Clinical trial
A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection
NCT04749368 is registered in ClinicalTrials.gov with Brii Biosciences Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection
- Lead sponsor
- Brii Biosciences Limited
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 12, 2021
- Completion date
- July 4, 2023
- Enrollment
- 91 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.